Therefore, anti-TNFR1 therapeutics hold great promise as effective treatments for inflammatory diseases of the nervous system like MS, because they efficiently block pro-inflammatory signaling via TNFR1 while leaving regenerative and immunomodulatory TNFR2 signaling intact (10). This evidence concerns the gene TNFRSF1B and myeloid sarcoma.